Amylyx’s neuron-protecting drug slows ALS decline in late-phase study

This post was originally published on this siteThe drug’s protective effects were seen across all the types of questions on an ALS rating scale, but the most sensitive categories appeared

Read More

ESC: Novartis’ twice-yearly inclisiran cuts bad cholesterol by at least 30% in nearly all patients

This post was originally published on this siteThough enrollment in a long-term phase 3 study was paused this year due to the pandemic, a new pooled analysis of two trials showed consistent

Read More

Novartis’ asciminib bests Pfizer’s Bosulif in phase 3 leukemia trial

This post was originally published on this siteNovartis’ asciminib has outperformed Pfizer’s Bosulif in a phase 3 chronic myeloid leukemia (CML) study, moving it closer to winning

Read More

Bayer to pay $1.6B to settle 90% of Essure injury claims

This post was originally published on this siteEarlier this month, the FDA published a list of publicly available social media posts related to certain Essure plaintiffs, which Bayer is required

Read More

FDA rejects Gilead’s would-be blockbuster filgotinib over toxicity concerns

This post was originally published on this siteThe FDA has rejected Gilead’s filing for approval of filgotinib in rheumatoid arthritis. With the FDA asking to see data from an ongoing

Read More

Hits, but mostly misses for Roche’s 4 late-stage trials of GI drug hopeful etrolizumab

This post was originally published on this siteRoche’s batch of phase 3 tests of its experimental GI drug etrolizumab has not gone to plan, with “mixed results” highlighting a

Read More

India’s Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test

This post was originally published on this siteZydus Cadila has completed (PDF) a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase

Read More

AstraZeneca bets $1B on Daiichi rival to Immunomedics’ Trodelvy

This post was originally published on this siteAstraZeneca is set to pay Daiichi Sankyo $1 billion to co-develop the antibody-drug conjugate (ADC) DS-1062 outside of Japan. The deal, which

Read More

FDA authorizes first COVID-19 test for screening people without symptoms

This post was originally published on this siteThe FDA issued its first authorization for pooled testing to Quest Diagnostics last week, in preparation for a new, long-term surveillance phase

Read More

Synairgen shares soar 300% on COVID treatment, but caveats abound

This post was originally published on this siteA U.K. biotech has seen its shares skyrocket on new data out from its experimental treatment in hospitalized COVID-19 patients, but it’s too

Read More